News

In accordance with the FDA's standard review designation, the agency has established a user fee goal date under the Prescription Drug User Fee Act (PDUFA) of February 12,

The company has reported positive data from the primary analysis of the phase III Haven 1 study in adults and adolescents and interim analysis of the phase III

Imraldi has been recommended to be approved for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease,

According to Pfizer, the letter is related to points made by the regulator in a February-issued warning letter after a routine inspection of the pharma’s McPherson facility in

Founding investor Versant Ventures co-led the round with MPM Capital. They were also joined by other syndicate investors including Fonds de solidarité FTQ, Celgene Switzerland, an affiliate of

Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the

The topline results from the trial have showed that the drug in combination with standard of care ACZ885 reduces the risk of major adverse cardiovascular events (MACE), a

Shingrix is being developed for the prevention of shingles, better known than herpes zoster, a painful, itchy rash condition caused by reactivation of latent chickenpox virus. The vaccine

ImmunoCellular has determined that the Company is unable at this time to secure sufficient additional financial resources to complete the phase 3 registration trial of ICT-107. As a